ISBN-10:
0898385806
ISBN-13:
9780898385809
Pub. Date:
04/30/1983
Publisher:
Springer US
Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment: Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA, October 26 and 27, 1982 / Edition 1

Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment: Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA, October 26 and 27, 1982 / Edition 1

by J. Morganroth, E. Neil Moore

Hardcover

Current price is , Original price is $249.99. You
Select a Purchase Option (1983)
  • purchase options
    $249.99
  • purchase options

Product Details

ISBN-13: 9780898385809
Publisher: Springer US
Publication date: 04/30/1983
Series: Developments in Cardiovascular Medicine , #25
Edition description: 1983
Pages: 302
Product dimensions: 6.20(w) x 9.30(h) x 0.90(d)

Table of Contents

New Antiarrhythmic Agents: Basic Considerations.- Do animal models predict results in man?.- Application of pharmacologic principles in the evaluation of new antiarrhythmic agents.- Characterization of antiarrhythmic drugs.- Panel Discussion: New antiarrhythmic agents: basic considerations.- Efficacy Models For Patients With Chronic Ventricular Arrhythmias.- How should ventricular arrhythmias be classified and which patients should be treated?.- Study design for patients with chronic ventricular ectopy: determination of efficacy and tolerance.- Chronic tolerance to antiarrhythmic therapy How to handle emergency drug requests.- Panel Discussion: Efficacy models for patients with chronic ventricular arrhythmias.- Efficacy Models: Acute Ventricular Arrhythmias.- The value of electrophysiologic testing in predicting long-term efficacy of antiarrhythmic drugs in patients with life-threatening ventricular arrhythmias.- Efficacy models: acute ventricular arrhythmias.- A look to the future: outpatient placebo controlled trials of antiarrhythmic drug efficacy in patients with life-threatening ventricular arrhythmias.- Panel Discussion: Efficacy models: acute ventricular arrhythmias.- Sudden Death: Can it Now be Used as an Endpoint?.- Protocol design for sudden death prevention.- Do beta blockers prevent sudden cardiac death?.- Does non beta-blocking antiarrhythmic therapy prevent sudden cardiac death?.- Current problems in the evaluation and approval of new antiarrhythmic agents.- Panel Discussion: Sudden death: can it now be used as an endpoint?.- New Devices: Pacemakers in the Treatment of Arrhythmias and Prevention of Sudden Cardiac Death.- New devices: pacemakers in the treatment of arrhythmias and prevention of sudden cardiac death.- Transvenous cardioversion to treat tachyarrhythmias.- The role of permanently implanted pacemakers in the therapy of recurrent tachyarrhythmias.- Clinical evaluation of an implantable automatic cardioverter defibrillator.- Evaluation of devices for the prevention of sudden death: study design for safety and efficacy of the devices.- New device approval by the Food and Drug Administration.- Panel Discussion: New devices: pacemakers in the treatment of arrhythmias and prevention of sudden cardiac death.- New Cardiac Inotropic Agents.- Pharmacologic principles in the use of new inotropic agents.- The clinical assessment of A inotropic drugs.- Panel Discussion: New cardiac inotropic agents.- Conclusion: Remarks by Arthur Hull Hayes, Jr., Commissioner of Food and Drugs.- List of Participants.

Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews